A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01
Abstract Background Pediatric low-grade gliomas (PLGG) are the most frequent brain tumors in children. Up to 50% will be refractory to conventional chemotherapy. It is now known that the majority of PLGG have activation of the MAPK/ERK pathway. The same pathway is also activated in plexiform neurofi...
Main Authors: | Sébastien Perreault, Valérie Larouche, Uri Tabori, Cynthia Hawkin, Sarah Lippé, Benjamin Ellezam, Jean-Claude Décarie, Yves Théoret, Marie-Élaine Métras, Serge Sultan, Édith Cantin, Marie-Ève Routhier, Maxime Caru, Geneviève Legault, Éric Bouffet, Lucie Lafay-Cousin, Juliette Hukin, Craig Erker, Nada Jabado |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-12-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-019-6442-2 |
Similar Items
-
Trametinib therapy for children with neurofibromatosis type 1 and life‐threatening plexiform neurofibroma or treatment‐refractory low‐grade glioma
by: Rebecca Ronsley, et al.
Published: (2021-06-01) -
Celecoxib as a Valuable Adjuvant in Cutaneous Melanoma Treated with Trametinib
by: Diana Valentina Tudor, et al.
Published: (2021-04-01) -
Ocular toxicity due to Trametinib and Dabrafenib
by: Stephanie Sarny, et al.
Published: (2017-08-01) -
Inhibition of ISG15 Enhances the Anti-Cancer Effect of Trametinib in Colon Cancer Cells
by: Zhou S, et al.
Published: (2019-11-01) -
Isotretinoin for the treatment of severe acneiform eruptions associated with the MEK inhibitor trametinib
by: Marco Caruana, MD, et al.
Published: (2020-10-01)